TPA023, formerly known as MK 0777, is an anxiolytic agent and a subtype-selective, mixed agonist-antagonist at GABAA receptors, which acts as a partial agonist at the α2 and α3 subtypes, but as a silent antagonist at α1 and α5 subtypes. It has primarily anxiolytic and anticonvulsant effects in animal tests, but with no sedative effects even at 50× the effective anxiolytic dose. In human trials on healthy volunteers, TPA-023 was comparable to lorazepam, but had much less side effects on cognition, memory, alertness or coordination. References: Wang M, Li Y, Lin Y. GABAA receptor α2 subtype activation suppresses retinal spreading depression. Neuroscience. 2015 Jul 9;298:137-44. doi: 10.1016/j.neuroscience.2015.04.016. Epub 2015 Apr 18. PubMed PMID: 25896802.

纯度：≥98%

CAS：252977-51-8